{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:38:58Z","timestamp":1791819538665,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Delta-like protein 3 (DLL3), a Notch ligand, has been identified in high-grade small- and large-cell lung carcinomas and prostate neuroendocrine carcinomas (NECs). SEZ6 (Seizure-related 6 homolog), a membrane-associated protein, has also been identified neuroendocrine neoplasms (NENs). Both DLL3 and SEZ6 are targets of novel antibody\u2013drug conjugates (ADCs). Their expression in the broader family of NENs remains to be clarified. We examined a series of NENs of all types as well as several non-neuroendocrine neoplasms using immunohistochemistry for DLL3 and SEZ6. Staining was scored with the semi-quantitative assessment of intensity and percentage of stained cells that yields a histoscore (H-score from 0 to 300). We identified strong expression of DLL3 in all lung NECs (average H-score 180) and SEZ6 in 1 of 3 (H-score 70). Merkel cell carcinomas (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200913) expressed DLL3 strongly and diffusely (H-score 178, range 10\u2013300) and 10 of 13 had positivity for SEZ6 (H-score 128). Both DLL3 and SEZ6 were expressed in medullary thyroid carcinomas (10 of 11 cases, H-scores 199 for DLL3 and 224 for SEZ6). Two thymic neuroendocrine tumors (NETs) had weak expression of DLL3 (H-score 20) and SEZ6 (H-score 70). Nine of 11 lung NETs expressed DLL3 (H-score 191), while only two had focal weak staining for SEZ6 (H-score 45). DLL3 was negative in nine of 11 pancreatic NETs; two grade 3 pancreatic NETs had variable weak positivity (H-score 5). In contrast, seven of 11 pancreatic NETs expressed SEZ6 (H-score 45). DLL3 was positive in two pancreatic NECs (H-score 197), and SEZ6 was positive in 1 (H-score 60). One of 13 gastric NETs, a metastatic grade 3 tumor, expressed both DLL3 and SEZ6 (H-score 200 for each) and one other expressed SEZ6 at lower levels. A gastric NEC was weakly positive for both markers (H-scores 50 and 40). All 10 duodenal, 10 ileal, and nine rectal NETs were negative for DLL3; eight duodenal, six ileal, and four rectal NETs expressed SEZ6 (average H-scores 206, 78 and 45, respectively). Among 10 appendiceal NETs, two expressed DLL3 focally and weakly (H-score 45); eight were positive for SEZ6 (H score 109). Duodenal NECS (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092) were negative for DLL3; one duodenal NEC expressed SEZ6 (H-score 110). Among five colonic NECs, two expressed DLL3 (H-score 50) and one expressed SEZ6 (H-score 40). Pituitary NETs also expressed DLL3 with eight of 18 positive (H-scores from 10 to 180), and 11 of 18 expressed SEZ6 (average H-score 65). Three of 20 paragangliomas expressed DLL3 weakly (H-score 43), and six expressed SEZ6 (H-score 73). One of four parathyroid carcinomas expressed DLL3 weakly (H-score 30), and all four were negative for SEZ6; five parathyroid adenomas were negative for both. In 43 non-neuroendocrine neoplasms of the GI tract, pancreas, and liver and 10 non-neuroendocrine thyroid carcinomas, there was only weak focal reactivity for DLL3 in three and two cases, respectively, and for SEZ6 in one case each. These results suggest that expression of DLL3 and SEZ6 varies among NENs of almost all types. Expression appears to be limited primarily to NENs and is rarely seen only focally and weakly in non-NENs. The presence of one or both of these antigens offers a novel approach to the treatment of patients with neuroendocrine neoplasms across the entire spectrum.\n                  <\/jats:p>","DOI":"10.1007\/s12022-025-09873-0","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T03:02:44Z","timestamp":1753239764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia"],"prefix":"10.1007","volume":"36","author":[{"given":"Iqbal","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6962-3535","authenticated-orcid":false,"given":"Amr","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-3936","authenticated-orcid":false,"given":"Omid","family":"Savari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-1806","authenticated-orcid":false,"given":"Yue","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-5054","authenticated-orcid":false,"given":"Sylvia L.","family":"Asa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"9873_CR1","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1242\/dev.124.16.3065","volume":"124","author":"SL Dunwoodie","year":"1997","unstructured":"Dunwoodie SL, Henrique D, Harrison SM, Beddington RS: Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 1997, 124:3065-3076.","journal-title":"Development"},{"key":"9873_CR2","doi-asserted-by":"crossref","unstructured":"Turnpenny PD, Bulman MP, Frayling TM, Abu-Nasra TK, Garrett C, Hattersley AT, Ellard S: A gene for autosomal recessive spondylocostal dysostosis maps to 19q13.1-q13.3. Am J Hum Genet 1999, 65:175\u2013182.","DOI":"10.1086\/302464"},{"key":"9873_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/jmg.40.5.333","volume":"40","author":"PD Turnpenny","year":"2003","unstructured":"Turnpenny PD, Whittock N, Duncan J, Dunwoodie S, Kusumi K, Ellard S: Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis. J Med Genet 2003, 40:333-339.","journal-title":"J Med Genet"},{"key":"9873_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","volume":"8","author":"AG Serrano","year":"2024","unstructured":"Serrano AG, Rocha P, Freitas LC, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM: Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 2024, 8:268.","journal-title":"NPJ Precis Oncol"},{"key":"9873_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","volume":"36","author":"M Schmitt","year":"2025","unstructured":"Schmitt M, Bohnenberger H, Bartsch DK, Wagner DC, Litmeyer AS, Grass A, Rinke A, Koch C, Kremer M, Evert M, Markl B, Quaas A, Eckstein M, Steinestel K, Denkert C, Steiger K, Kloppel G, Kasajima A, Tschurtschenthaler M, Foersch S, Jesinghaus M: DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms. Endocr Pathol 2025, 36:9.","journal-title":"Endocr Pathol"},{"key":"9873_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12022-020-09657-8","volume":"32","author":"C Liverani","year":"2021","unstructured":"Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di MG, Foca F, Ravaioli S, De VA, Cocchi C, Rossi G, Recine F, Ibrahim T: Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021, 32:309-317.","journal-title":"Endocr Pathol"},{"key":"9873_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0925-4773(02)00238-1","volume":"118","author":"MH Kim","year":"2002","unstructured":"Kim MH, Gunnersen JM, Tan SS: Localized expression of the seizure-related gene SEZ-6 in developing and adult forebrains. Mech Dev 2002, 118:171-174.","journal-title":"Mech Dev"},{"key":"9873_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1006\/bbrc.1995.2635","volume":"216","author":"K Shimizu-Nishikawa","year":"1995","unstructured":"Shimizu-Nishikawa K, Kajiwara K, Sugaya E: Cloning and characterization of seizure-related gene, SEZ-6. Biochem Biophys Res Commun 1995, 216:382-389.","journal-title":"Biochem Biophys Res Commun"},{"key":"9873_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00784-7","volume":"9","author":"A Ajay","year":"2025","unstructured":"Ajay A, Wang H, Rezvani A, Savari O, Grubb BJ, McColl KS, Yoon S, Joseph PL, Kopp SR, Kresak AM, Peacock CD, Wildey GM, Lam M, Miyagi M, Kao HY, Dowlati A: Assessment of targets of antibody drug conjugates in SCLC. NPJ Precis Oncol 2025, 9:1.","journal-title":"NPJ Precis Oncol"},{"key":"9873_CR10","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1210\/clinem\/dgae672","volume":"110","author":"B Xu","year":"2025","unstructured":"Xu B, Baine MK, Jungbluth A, Alabkaa A, Serrette R, Roy D, Rudin CM, Ho AL, Sherman E, Dogan S, Ganly I, Rekhtman N, Ghossein R: Detection of SEZ6, a Therapeutic Target, in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 2025, 110:2041-2046.","journal-title":"J Clin Endocrinol Metab"},{"key":"9873_CR11","doi-asserted-by":"crossref","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015, 7:302ra136.","DOI":"10.1126\/scitranslmed.aac9459"},{"key":"9873_CR12","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.1158\/1078-0432.CCR-24-1547","volume":"30","author":"D Morgensztern","year":"2024","unstructured":"Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M: A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clin Cancer Res 2024, 30:5042-5052.","journal-title":"Clin Cancer Res"},{"key":"9873_CR13","unstructured":"WHO Classification of Tumours Editorial Board: WHO classification of endocrine and neuroendocrine tumours. 5th edition. Lyon, France: IARC; 2022."},{"key":"9873_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A: Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol 2022, 33:90-114.","journal-title":"Endocr Pathol"},{"key":"9873_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La RS, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL: Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 2022, 33:115-154.","journal-title":"Endocr Pathol"},{"key":"9873_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY: Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 2022, 33:6-26.","journal-title":"Endocr Pathol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09873-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:25:58Z","timestamp":1767860758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09873-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9873"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09873-0","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"11 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was from the University Hospitals Cleveland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}